Photoselective sharp enucleation helps in effective treatment of BPH: BMC

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-12-09 14:30 GMT   |   Update On 2022-12-10 06:41 GMT

In case of benign prostatic hyperplasia (BPH), photoselective sharp enucleation of the prostate (PSEP) removes more tissue than photoselective vaporization of the prostate (PVP)  and is effective and safe for treatment. This study was published in the BMC Urology.

This study by Zhengchao Liu and peers included a total of 154 patients from June 2018 to April 2019 who were diagnosed with bladder outlet obstruction additional to BPH were divided randomly into PSEP and the PVP group. Preoperatively all the patients were assessed and postoperatively followed up at 1, 6, and 12 months. Between the treatment options international prostate symptom score, quality-of-life score, postvoid residual urine volume, maximum urine flow rate, prostate volume, prostate-specific antigen, and adverse events were compared .

The findings of this study were:

  • Postoperatively, lower urinary tract symptoms in both groups were significantly improved compared with the baseline at 1, 6, and 12 months.
  • At each follow up, both the groups had an equivalent International Prostate Symptom Score, quality-of-life score, postvoid residual urine volume, maximum urine flow rate and prostate-specific antigen.
  • The median operative time in the PSEP group was significantly shorter than that in the PVP group (35 min vs. 47 min, P < 0.001).
  • The median Prostate Volume in the PSEP group was comparatively smaller than the PVP group at 6 months and 12 months following surgery.

The authors suggest that PSEP can remove more tissue compared to PVP and it eliminates the lack of tissue samples problem, this can highly reduce the risk of missed prostate cancer diagnosis. 

Reference:

Liu, Z., Chen, Z., Yan, D., Jiang, T., Fu, J., Zheng, J., Zhou, Y., Zhou, Z., & Shen, W. (2022). Photoselective sharp enucleation of the prostate with a front-firing 532-nm laser versus photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia: a randomised controlled trial with 1-year followup results. In BMC Urology. Springer Science and Business Media LLC. https://doi.org/10.1186/s12894-022-01129-x

Tags:    
Article Source : BMC Urology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News